revance.comHome - Revance

Company Leadership Board Partnerships Sustainability Medical Educational Grants Investigator sponsored trials Products and Pipeline Investors Investor Relations Press Releases Events + Presentations Corporate Governance Financials and Filings Stock Information Analyst Coverage Investor FAQ Media Contacts Careers Opportunities Culture Benefits Privacy Notice News Contact Us LOGINCompany Leadership Board Partnerships Sustainability Medical Educational Grants Investigator Sponsored Trials Products and Pipelines Aesthetics Pipeline Therapeutics Pipeline Clinical Highlights Investors Investor Relations Press Releases Events + Presentations Financials and Filings Corporate Governance Stock Information Analyst Coverage Media Contacts FAQ IR Contacts Careers Opportunities Culture Privacy Notice Benefits & Perks News Contact Us The Only Long-Lasting, Peptide-Powered Frown Line Treatment. FIND DAXXIFY® NEAR ME Press Releases May 9, 2024 Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update May 9, 2024 Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia May 2, 2024 Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 OUR PRODUCTS AND PIPELINE Revance is setting the new standard in healthcare by elevating patient and physician experiences through the development, acquisition and commercialization of innovative aesthetic and therapeutic offerings. View Pipeline AESTHETICS pipeline Long Acting Neuromodulator Hyaluronic Acid Filler therapeutics pipeline LONG ACTING NEUROMODULATOR Investors relations Grow With Revance We are backed by 20 years of investment in R&D, a diverse portfolio of products and rapid, year after year growth. Learn more CAREERS Shift your career to Revance At Revance, our success is directly shaped by our highly qualified and motivated people across our brands. We are always looking for great talent to join Revance. To learn more about a career at Revance, please visit our career page. explore opportunities INDICATION DaxibotulinumtoxinA for Injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DaxibotulinumtoxinA for Injection and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DaxibotulinumtoxinA for Injection is not approved for the treatment of spasticity or any conditions other than glabellar lines. IMPORTANT SAFETY INFORMATION Contraindications DaxibotulinumtoxinA for Injection contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s). Warnings and Precautions Please refer to Boxed Warning for Distant Spread of Toxin Effect. The potency Units of DaxibotulinumtoxinA for Injection are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment. Adverse Reactions The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%). Drug Interactions Co-administration of DaxibotulinumtoxinA for Injection and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DaxibotulinumtoxinA for Injection may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DaxibotulinumtoxinA for Injection is unknown. Use in Specific Populations DaxibotulinumtoxinA for Injection is not recommended for use in children or pregnant women. Please see DaxibotulinumtoxinA for Injection full Prescribing Information, including Boxed Warning and Medication Guide. IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) injection DAXXIFY® may cause serious side effects that can be life threatening. Read More DAXXIFY ® (daxibotulinumtoxinA-lanm) injection IMPORTANT SAFETY INFORMATION Indications (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults. WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines. IMPORTANT SAFETY INFORMATION Contraindications DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s). Warnings and Precautions Please refer to Boxed Warning for Distant Spread of Toxin Effect. The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment. Adverse Reactions The most commonly observed adverse reactions are: Glabeller lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%). Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%). Drug Interactions Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown. Use in Specific Populations DAXXIFY® is not recommended for use in children or pregnant women. Please see DAXXIFY® full Prescribing Information , including Boxed Warning and Medication Guide . To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch DAXI-004726 Company PRODUCTS AND PIPELINE Leadership Team Board Partnerships Contact Us Sustainability Medical Educational Grants Investigator Sponsored Trials CALIFORNIA COMPLIANCE DECLARATION Investors Investor Relations Financials And Filings Corporate Governance Analyst coverage FAQ Press Releases Careers Opportunities Culture Benefits Privacy Notice Media News Company PRODUCTS AND PIPELINE LEADERSHIP TEAM BOARD PARTNERSHIPS CONTACT US SUSTAINABILITY MEDICAL EDUCATIONAL GRANTS INVESTIGATOR SPONSORED TRIALS CALIFORNIA COMPLIANCE...